|
Update - Application for quotation of securities - AVE
|
28 June 2023 at 12:15pm
|
|
Application for quotation of securities - AVE
|
28 June 2023 at 12:10pm
|
|
AVE CBD capsule passes two-year stability milestone
|
22 June 2023 at 9:20am
|
|
AVE adds TPM cannabinoid gummies to portfolio
|
7 June 2023 at 9:45am
|
|
USPTO allows new TPM manufacturing patent
|
29 May 2023 at 9:40am
|
|
2023 Annual General Meeting Results
|
23 May 2023 at 3:40pm
|
|
Chair's Address and CEO Presentation
|
23 May 2023 at 1:15pm
|
|
Avecho licenses TPM for use in cancer drugs
|
22 May 2023 at 10:05am
|
|
Withdrawal of AGM Resolutions 5(c) and 5(d)
|
18 May 2023 at 9:15am
|
|
AVE commences manufacturing for Phase III trial
|
17 May 2023 at 9:45am
|
|
Change in Substantial Holding
|
16 May 2023 at 9:10am
|
|
Change of Director's Interest Notice x2
|
10 May 2023 at 9:40am
|
|
Top 20 Option Holders
|
10 May 2023 at 9:30am
|
|
Application for quotation of securities - AVE
|
10 May 2023 at 9:30am
|
|
Results of Entitlement Offer
|
9 May 2023 at 9:05am
|
|
Receipt of R&D Tax Incentive
|
2 May 2023 at 1:00pm
|
|
March 2023 Quarterly Activities Report & Appendix 4C
|
28 April 2023 at 9:50am
|
|
Notice of Annual General Meeting/Proxy Form
|
21 April 2023 at 9:05am
|
|
Notice to Ineligible Foreign Shareholders
|
13 April 2023 at 9:00am
|
|
Notice to Eligible Shareholders
|
13 April 2023 at 9:00am
|
|
Letter to Optionholders
|
3 April 2023 at 10:55am
|
|
Target Market Determination
|
3 April 2023 at 10:55am
|
|
Proposed issue of securities - AVE
|
3 April 2023 at 10:55am
|
|
Investor Presentation
|
3 April 2023 at 10:50am
|
|
Prospectus
|
3 April 2023 at 10:10am
|
|
Entitlement Offer to raise $11m for Phase 3 clinical trial
|
3 April 2023 at 10:05am
|
|
Avecho to present at NWR Virtual Healthcare Conference
|
17 March 2023 at 10:00am
|
|
Appendix 4G and Corporate Governance Statement
|
15 March 2023 at 5:55pm
|
|
Annual Report - 31 December 2022
|
15 March 2023 at 5:55pm
|
|
Appendix 4E - Preliminary Final Report
|
28 February 2023 at 9:40am
|
|
Clinical CBD program expands with the Lambert Initiative
|
22 February 2023 at 8:50am
|
|
December 2022 Quarterly Activities Report & Appendix 4C
|
31 January 2023 at 9:00am
|
|
Athenex submits Avecho's phytonadione to FDA pre-IND
|
12 January 2023 at 12:10pm
|
|
Avecho receives ethics approval for Phase III CBD trial
|
22 December 2022 at 10:20am
|
|
AVE signs development agreement with Perrigo
|
20 December 2022 at 9:20am
|
|
September 2022 Quarterly Activities Report & Appendix 4C
|
28 October 2022 at 9:00am
|
|
Increased CBD absorption in dogs vs commercial comparator
|
19 September 2022 at 10:25am
|
|
Application for quotation of securities - AVE
|
1 September 2022 at 9:40am
|
|
Section 708A Cleansing Statement
|
1 September 2022 at 9:25am
|
|
Appendix 4D and Half-year Financial Report
|
29 August 2022 at 9:35am
|
|
June 2022 Quarterly Activities Report & Appendix 4C
|
29 July 2022 at 8:59am
|
|
Security Class Reinstatement to Quotation- AVEO
|
14 July 2022 at 5:10pm
|
|
Update on Listed Options and Federal Court Application
|
14 July 2022 at 5:10pm
|
|
Suspension from Official Quotation - AVEO
|
8 June 2022 at 10:05am
|
|
Adoption of New Constitution
|
30 May 2022 at 4:40pm
|
|
2022 Annual General Meeting Results
|
30 May 2022 at 4:40pm
|
|
Chair's Address and CEO Presentation
|
30 May 2022 at 12:55pm
|
|
Receipt of R&D Tax Incentive
|
3 May 2022 at 12:55pm
|
|
March 2022 Quarterly Activities Report & Appendix 4C
|
29 April 2022 at 9:05am
|
|
Notice of Annual General Meeting/Proxy Form
|
28 April 2022 at 5:50pm
|
Avecho Biotechnology